Claims
- 1. The ligand represented by general structure 1:
- 2. The ligand of claim 1, wherein X and Y are not identical;
R is selected, independently for each occurrence, from the set consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH2)m—R80; R1, R2, R3, and R4 are selected, independently for each occurrence, from the set consisting of H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, —SiR3, and —(CH2)m—R80; and R5 and R6 are selected, independently for each occurrence, from the set consisting of H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, —SiR3, and —(CH2)m—R80.
- 3. The ligand of claim 1, wherein X is hydrogen; and Y is PR2.
- 4. The ligand of claim 3, wherein R is alkyl.
- 5. The ligand represented by general structure 2:
- 6. The ligand of claim 5, wherein:
X and Y are not identical; R is selected, independently for each occurrence, from the set consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH2)m—R80; R1, R2, R3, R4, R5, R6, R7, and R8 are selected, independently for each occurrence, from the set consisting of H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, —SiR3, and —(CH2)m—R80.
- 7. The ligand of claim 5, wherein X is hydrogen; and Y is PR2.
- 8. The ligand of claim 7, wherein R is alkyl.
- 9. The ligand represented by general structure 3:
- 10. The ligand of claim 9, wherein:
X and Y are not identical; R is selected, independently for each occurrence, from the set consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and —(CH2)m—R80; R1, R2, R3, and R4 are selected, independently for each occurrence, from the set consisting of H, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, —SiR3, and —(CH2)m—R80; and R5 and R6 are selected, independently for each occurrence, from the set consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroatalkyl, halogen, —SiR3, and —(CH2)m—R80.
- 11. The ligand of claim 9, wherein X is hydrogen; and Y is PR2.
- 12. The ligand of claim 11, wherein R is alkyl.
- 13. The ligand represented by general structure 4:
- 14. The ligand of claim 13, wherein:
R1 and R2 are absent; both instances of R on the N depicted explicitly are lower alkyl; and both instances of R on P depicted explicitly are cycloalkyl.
- 15. The ligand represented by general structure 5:
- 16. The ligand of claim 15, wherein:
R1, R2, R3, and R4, are absent; and all instances of R are lower alkyl or cycloalkyl.
- 17. The ligand represented by general structure 6:
- 18. The ligand of claim 17, wherein:
R1 and R2 are absent; and all instances of R are lower alkyl or cycloalkyl.
- 19. The ligand represented by general structure 7:
- 20. The ligand of claim 19, wherein:
R1, R2, R3, and R4, are absent; both instances of R on the N depicted explicitly are lower alkyl; and both instances of R on P depicted explicitly are cycloalkyl.
- 21. The method depicted in Scheme 1:
- 22. The method of claim 21, wherein:
the ligand is 2; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 23. The method of claim 21 or 22, wherein:
the ligand is 2, wherein X is hydrogen, and Y represents P(alkyl)2; and X represents Cl or Br.
- 24. The method of claim 21, wherein:
the ligand is 4; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 25. The method of claim 22, wherein:
the ligand is 4, wherein R1 and R2 are absent; P(R)2 represents PCy2, and N(R)2 represents NMe2; and X represents Cl or Br.
- 26. The method of claim 21, wherein: HN(R′)R″ represents an optionally substituted heteroaromatic compound.
- 27. The method of claim 21, wherein: X represents Cl; the ligand is 4, wherein R1 and R2 are absent, P(R)2 represents PCy2, and N(R)2 represents NMe2; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 28. The method of claim 21, wherein: X represents Br or I; the ligand is 4, wherein R1 and R2 are absent, P(R)2 represents PCy2, and N(R)2 represents NMe2; the transition metal is palladium; the base is an alkoxide, amide, phosphate, or carbonate; and the transformation occurs at room temperature.
- 29. The method of claim 21, wherein: the ligand is 5; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 30. The method of claim 21, wherein: X represents Cl; the ligand is 5, wherein R1, R2, R3, and R4 are absent, and all occurrences of R are cyclohexyl; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 32. The method of claim 21, wherein: the ligand is 2, wherein X and Y both represent P; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 33. The method of claim 21, wherein: X represents Cl; the ligand is 2, wherein X and Y both represent P, R1, R2, R3, R4, R5, R6, R7, and R8 are absent, and all occurrences of R are cyclohexyl; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 34. The method of claim 21, wherein (alkenyl)X serves as a surrogate for ArX.
- 35. The method of claim 21, wherein the product is provided in a yield of greater than 50%.
- 36. The method of claim 21, wherein the product is provided in a yield of greater than 70%.
- 37. The method of claim 21, wherein the product is provided in a yield of greater than 85%.
- 38. The method of claim 21, wherein the reaction occurs at ambient temperature.
- 39. The method of claim 21, wherein the catalyst complex is present in less than 0.01 mol % relative to the limiting reagent.
- 40. The method of claim 21, wherein the catalyst complex is present in less than 0.0001 mol % relative to the limiting reagent.
- 41. The method depicted in Scheme 2:
- 42. The method of claim 41, wherein
the ligand is 2; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 43. The method of claim 41 or 42, wherein
the ligand is 2, wherein X is hydrogen, and Y represents P(alkyl)2; and X represents Cl or Br.
- 44. The method of claim 41, wherein:
the transition metal is palladium; the ligand is 4; and the base is an alkoxide, amide, carbonate, phosphate, or fluoride.
- 45. The method of claim 41, wherein:
the ligand is 4, wherein R1 and R2 are absent; P(R)2 represents PCy2, and N(R)2 represents NMe2; X represents Cl or Br; and the reaction occurs at room temperature.
- 46. The method of claim 41, wherein (alkenyl)X serves as a surrogate for ArX, and/or (alkenyl)B(OH)2 serves as a surrogate for ArB(OH)2.
- 47. The method of claim 41, wherein the product is provided in a yield of greater than 50%.
- 48. The method of claim 41, wherein the product is provided in a yield of greater than 70%.
- 49. The method of claim 41, wherein the product is provided in a yield of greater than 85%.
- 50. The method of claim 41, wherein the reaction occurs at ambient temperature.
- 51. The method of claim 41, wherein the catalyst complex is present in less than 0.01 mol % relative to the limiting reagent.
- 52. The method of claim 41, wherein the catalyst complex is present in less than 0.0001 mol % relative to the limiting reagent.
- 53. The method depicted in Scheme 3:
- 54. The method of claim 53, wherein the ligand is 2;
the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 55. The method of claim 53 or 54, wherein:
the ligand is 2, wherein X is hydrogen, and Y represents P(alkyl)2; and X represents Cl or Br.
- 56. The method of claim 53, wherein
X represents Cl or Br; the transition metal is palladium; the ligand is 4; and the base is an alkoxide, amide, carbonate, phosphate, or fluoride.
- 57. The method of claim 53, wherein
the ligand is 4, wherein R1 and R2 are absent; P(R)2 represents PCy2, and N(R)2 represents NMe2; and X represents Cl.
- 58. The method of claim 53, wherein (alkenyl)X serves as a surrogate for ArX.
- 59. The method of claim 53, wherein the product is provided in a yield of greater than 50%.
- 60. The method of claim 53, wherein the product is provided in a yield of greater than 70%.
- 61. The method of claim 53, wherein the product is provided in a yield of greater than 85%.
- 62. The method of claim 53, wherein the reaction occurs at ambient temperature.
- 63. The method of claim 53, wherein the catalyst complex is present in less than 0.01 mol % relative to the limiting reagent.
- 64. The method of claim 53, wherein the catalyst complex is present in less than 0.0001 mol % relative to the limiting reagent.
- 65. The method depicted in Scheme 4:
- 66. The method of claim 65, wherein
the ligand is 2; the transition metal is palladium; and the base is an alkoxide, amide, phosphate, or carbonate.
- 67. The method of claim 65 or 66, wherein
the ligand is 2, wherein X is hydrogen, and Y represents P(alkyl)2; and X represents Cl or Br.
- 68. The method of claim 65, wherein
X represents Cl or Br; the transition metal is palladium; the ligand is 4; and the base is an alkoxide, or amide.
- 69. The method of claim 65, wherein
the ligand is 4, wherein R1 and R2 are absent; P(R)2 represents PCy2, and N(R)2 represents NMe2.
- 70. The method of claim 65, wherein
X represents Br; and the reaction occurs at room temperature.
- 71. The method of claim 65, wherein (alkenyl)X serves as a surrogate for ArX.
- 72. The method of claim 65, wherein the product is provided in a yield of greater than 50%.
- 73. The method of claim 65, wherein the product is provided in a yield of greater than 70%.
- 74. The method of claim 65, wherein the product is provided in a yield of greater than 85%.
- 75. The method of claim 65, wherein the reaction occurs at ambient temperature.
- 76. The method of claim 65, wherein the catalyst complex is present in less than 0.01 mol % relative to the limiting reagent.
- 77. The method of claim 65, wherein the catalyst complex is present in less than 0.0001 mol % relative to the limiting reagent.
- 78. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to provide the product at room temperature.
- 79. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to provide the product when X is chloride.
- 80. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to provide the product utilizing less than 0.01 mol % of the catalyst relative to the limiting reagent.
- 81. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to provide the product utilizing less than 0.0001 mol % of the catalyst relative to the limiting reagent.
- 82. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to consume the limiting reagent in less than 48 hours.
- 83. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to consume the limiting reagent in less than 24 hours.
- 84. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to consume the limiting reagent in less than 12 hours.
- 85. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to give the product in a yield of greater than 50% in less than 48 hours.
- 86. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to give the product in a yield of greater than 50% in less than 24 hours.
- 87. The method of claim 21, 41, 53, or 65, wherein the transition metal and ligand are selected to give the product in a yield of greater than 50% in less than 12 hours.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Ser. No. 09/113,478, filed Jul. 10, 1998.
GOVERNMENT FUNDING
[0002] The present invention was made with support provided by the National Institutes of Health; the government, therefore, has certain rights in the invention.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09231315 |
Jan 1999 |
US |
Child |
10004101 |
Oct 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09113478 |
Jul 1998 |
US |
Child |
09231315 |
Jan 1999 |
US |